Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia
Aberrant activity of the phosphatidylinositol‐3 kinase/protein kinase B/mammalian target of
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia
S Stengel, KR Petrie, Y Sbirkov… - British journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Aberrant activity of the phosphatidylinositol-3 kinase/protein kinase B/mammalian target of
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
S Stengel, KR Petrie, Y Sbirkov… - British Journal of …, 2022 - search.ebscohost.com
Aberrant activity of the phosphatidylinositol‐3 kinase/protein kinase B/mammalian target of
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
S Stengel, KR Petrie, Y Sbirkov, C Stanko… - British Journal of …, 2022 - europepmc.org
Aberrant activity of the phosphatidylinositol-3 kinase/protein kinase B/mammalian target of
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
S Stengel, K Petrie, Y Sbirkov… - British Journal of …, 2022 - sure.sunderland.ac.uk
Aberrant activity of the phosphatidylinositol-3 kinase/protein kinase B/mammalian target of
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
[PDF][PDF] Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia
S Stengel, KR Petrie, Y Sbirkov, C Stanko, FG Zadegan… - 2022 - researchgate.net
Aberrant activity of the phosphatidylinositol-3 kinase/protein kinase B/mammalian target of
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …
rapamycin (PI3K/AKT/mTOR [PAM]) pathway, as well as suppressed retinoic acid signalling …